Clinical Trial

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Media Release SYDNEY, AUSTRALIA, June 25, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),…

1 year ago

Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ:…

1 year ago

Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data

MALVERN, Pa., June 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),…

1 year ago

Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program

– BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes – – Humacyte’s stem cell-derived…

1 year ago

Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections

Positions RECCE® 327 (R327) gel as a potential broad topical therapeutic for all bacterial skin infectionsHuman Research Ethics Committee approval…

1 year ago

BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024

SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who…

1 year ago

Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film

Anaphylm pharmacokinetic results unaffected by oral cavity exposure to liquids of different temperatures and pHRemains on track to complete Anaphylm…

1 year ago

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC

SHANGHAI, June 25, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

1 year ago

Zevra Therapeutics Expands Executive Leadership Team

Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION,…

1 year ago

Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease

Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation…

1 year ago